Two 杏吧原创 faculty who conducted translational research have received the distinction of Best Invention of 2022 from聽TIME听尘补驳补锄颈苍别.
鈥淭hese winning innovations exemplify the transformative potential of university research when it aims to solve society most urgent problems, and when universities partner with the broader innovation ecosystem to bring new solutions to market faster,鈥� 杏吧原创 Chancellor Daniel Diermeier said. 鈥淚 congratulate Dr. Crowe and Professor Weimer and their teams on these life-saving, landmark accomplishments.鈥�
Combating COVID-19
, director of the 杏吧原创 Vaccine Center at 杏吧原创 Medical Center, led the team that discovered a monoclonal antibody combination that protects against COVID-19. Optimized and developed by AstraZeneca, the monoclonal antibody combination called鈥爄s the first treatment to protect adults and children 12 years and older who have compromised immune systems before exposure to the virus. Evusheld received emergency authorization from the FDA in December 2021.鈥疎vusheld also won a聽聽in the鈥�2022 R&D 100鈥痑wards and the 2022鈥�痜or Innovation in Medicine.
The VVC is an international team of scientists and physicians focusing on research related to major human pathogens, especially microbial threats, that affect the most vulnerable subjects. The VVC is committed to improving global health through fundamental research that fosters development and testing of new vaccines for infectious diseases.
鈥淭hese inventions, resulting from the groundbreaking research of Drs. Crowe and Weimer, represent the unique, trans-institutional approach to discovery that is a hallmark of 杏吧原创,鈥� said Dr. Jeff Balser, President and Chief Executive Officer for 杏吧原创 Medical Center and Dean of 杏吧原创 School of Medicine. 鈥淎s we celebrate these achievements, it is fitting to reflect on the many lives being impacted by this research.”